NOPE! Several changes have been made over the years (replacement of a randomized design with a synthetic control arm, removal of PFS as the primary endpoint, addition of a new study population, conduct of unplanned analyses), raising many questions about data interpretability
To confirm the results of DCVax-L, it would be ideal to design two new trials, one in the newly diagnosed GB setting and another in the relapsed-disease setting, both randomized, for comparison with the standard of care
Conflicts of Interest The authors declare no conflict of interest.
Market Data 
Markets 
AI
